Sepsis Guidelines: Current Recommendations (2024–2026)

Note: As of mid-2025, the landmark framework remains the Surviving Sepsis Campaign (SSC) 2021 Guidelines (published in Critical Care Medicine and Intensive Care Medicine). The SSC updates occur on a rolling/periodic basis; no entirely new standalone "2026 guideline" document has been released yet. What follows reflects the current authoritative guidance plus emerging updates.

1. Definitions (Sepsis-3, Still in Force)

2. Screening & Recognition

• Trigger tools incorporating vital signs, physical exam findings, and at-risk populations are recommended at the institutional level.
• Rapid clinician assessment within 15 minutes of trigger activation.
• Activation of a sepsis resuscitation bundle within 15 minutes for suspected septic shock (Hemodynamic Support of Pediatric and Neonatal Septic Shock, p. 17).

3. The "Hour-1 Bundle" (SSC 2021 Core Actions)

1. Measure lactate — remeasure if initial lactate > 2 mmol/L
2. Blood cultures before antibiotics (do NOT delay antibiotics to obtain cultures)
3. Broad-spectrum antibiotics within 1 hour of recognition
4. IV crystalloid 30 mL/kg for hypotension or lactate ≥ 4 mmol/L
5. Vasopressors if patient is hypotensive during/after fluids — target MAP ≥ 65 mmHg

4. Fluid Resuscitation — Key Updates

• Balanced crystalloids (e.g., Lactated Ringer's, Plasmalyte) are preferred over normal saline (0.9% NaCl), which is associated with hyperchloremic acidosis and AKI.
• The SSC and subsequent trials (SMART, BASICS, PLUS) reinforced this preference.
• Fluid stewardship is emphasized — the 30 mL/kg bolus is a starting point, not a mandate; reassess with dynamic measures (pulse pressure variation, stroke volume variation, passive leg raise).
• Avoid fluid overload — associated with worse outcomes, especially in ARDS and AKI.

5. Antimicrobial Therapy

• Antibiotics within 1 hour (strong recommendation for septic shock; best practice statement for sepsis without shock).
• Empiric broad-spectrum coverage tailored to suspected source, local resistance patterns, and patient risk factors (immunocompromise, prior MDR exposure).
• De-escalation once cultures and sensitivities are available — shorter courses are generally preferred.
• Procalcitonin can guide de-escalation and duration.
• Typical duration: 5–7 days for most infections; longer only with specific clinical indications.

6. Vasopressors & Hemodynamic Support

7. Corticosteroids

• Hydrocortisone 200 mg/day (continuous infusion or 50 mg q6h) recommended if adequate fluids and vasopressors fail to restore hemodynamic stability.
• Supported by APROCCHSS and ADRENAL trials.
• Not recommended routinely in sepsis without shock.

8. Mechanical Ventilation (Sepsis-Associated ARDS)

• Low tidal volume: 6 mL/kg predicted body weight
• Plateau pressure ≤ 30 cmH₂O
• High PEEP for moderate-severe ARDS (PaO₂/FiO₂ < 150)
• Prone positioning ≥ 16 hours/day for moderate-severe ARDS
• Neuromuscular blockade (cisatracurium) — selective use only
• Conservative oxygen strategy: target SpO₂ 92–96%

9. Source Control

• Identify and control the infectious source as rapidly as possible (within 6–12 hours where feasible).
• Remove infected devices, drain abscesses, débride necrotic tissue.
• Least invasive intervention adequate to achieve control is preferred.

10. Glucose & Metabolic Management

• Target blood glucose 140–180 mg/dL (7.8–10 mmol/L) using insulin protocol.
• Avoid hypoglycemia — more harmful than mild hyperglycemia in critical illness.

11. Pediatric Sepsis — Notable Differences

• IV/IO access within 5 minutes
• Fluid resuscitation initiated within 30 minutes
• Broad-spectrum antibiotics within 60 minutes
• Target MAP-CVP normal for age: 55 + 1.5 × age (years) mmHg
• ScvO₂ > 70% and/or CI 3.3–6.0 L/min/m²
• Inotrope (peripheral or central) within 60 minutes if needed

12. Emerging Areas (2024–2026 Horizon)

• Biomarker-guided therapy: Expanded use of procalcitonin, IL-6, presepsin for diagnosis and de-escalation.
• Personalized/precision medicine: Phenotyping sepsis into hyperinflammatory vs. hypo-inflammatory endotypes to guide immunomodulatory therapy.
• Vitamin C + thiamine: CITRIS-ALI and VICTAS trials showed no clear mortality benefit; routine use no longer supported.
• Revised pediatric sepsis definitions: The 2024 Phoenix criteria (published in JAMA) introduced new pediatric sepsis scoring — replacing prior pediatric SIRS-based definitions with organ dysfunction scoring adapted for children.
• Antibiotic stewardship integration: Tighter coupling of sepsis bundles with ID stewardship programs for earlier de-escalation.

Quick Reference Summary